3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Small Cell Lung Carcinoma
9
Carcinoma, Non-Small-Cell Lung
7
Sarcoma
5
Breast Neoplasms
4
Triple Negative Breast Neoplasms
3
Thyroid Neoplasms
3
Nasopharyngeal Carcinoma
3
Pancreatic Neoplasms
2
Neoplasm Metastasis
2
Esophageal Squamous Cell Carcinoma
2
Carcinoma, Renal Cell
2
Carcinoma, Hepatocellular
2
Whole-Brain Radiotherapy
1
Stomach Neoplasms
1
Solid Tumors
1
Small Cell Lung Cancer Extensive Stage
1
Sarcoma, Synovial
1
Sarcoma, Alveolar Soft Part
1
Recurrence
1
Proteinuria
1
Progression Free Survival(PFS)
1
Platinum-resistant Ovarian Cancer (PROC)
1
Ovarian Neoplasms
1
Lung Neoplasms
1
Leiomyosarcoma
1
HER2-Negative Breast Cancer
1
Gallbladder Neoplasms
1
Fallopian Tube Neoplasms
1
Extensive Stage Lung Small Cell Cancer
1
Esophageal Neoplasms
1
Interventions
Doxorubicin
6
Specimen Handling
5
Radiotherapy
3
Radiation
3
Nivolumab
3
Magnetic Resonance Spectroscopy
3
Gemcitabine
3
Biopsy
3
pembrolizumab
2
liposomal doxorubicin
2
eribulin
2
durvalumab
2
Ifosfamide
2
Dacarbazine
2
tremelimumab
1
toripalimab
1
talimogene laherparepvec
1
rucaparib
1
ribociclib
1
regorafenib
1
peposertib
1
pazopanib
1
olaratumab
1
olaparib
1
lenvatinib
1
futibatinib
1
dinutuximab
1
cemiplimab
1
cediranib
1
cabozantinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leiomyosarcoma
×
anlotinib
×
1 year
×
Clear all
NCT03016819
2026-02-25
APROMISS
Advenchen Laboratories, LLC
Phase 3
Recruiting
325 enrolled